New pill tested for Tough-to-Treat blood cancers
NCT ID NCT04018248
Summary
This first-in-human study tested a new oral drug called BR101801 in adults with advanced blood cancers that had returned or stopped responding to other treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Inje University Busan Paik Hospital
Busan, South Korea
-
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
-
Seoul national university hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.